{"id":"W2346128427","doi":"10.1158/1078-0432.ccr-15-2488","title":"Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma","year":2016,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Calicheamicin; Medicine; Rituximab; Gastroenterology; Internal medicine; Neutropenia; Tolerability; Leukopenia; Lymphoma; Febrile neutropenia; Adverse effect; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001050849,0.001394104,0.002252986,0.0003766625,0.0003625849,0.0008649345,0.001115573,0.0009547267,0.001737906],"category_scores_gemma":[0.0005938884,0.0006060809,0.000848027,0.0003843728,0.0009946798,0.0007045597,0.0003120712,0.002793438,0.0007436976],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009380387,"about_ca_system_score_gemma":0.001697895,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001085586,"about_ca_topic_score_gemma":0.002432322,"domain_scores_codex":[0.999629,0.0001635326,0.00002004565,0.00006970446,0.0000403295,0.00007740373],"domain_scores_gemma":[0.9994592,0.0000583992,0.0001061391,0.00006172687,0.00003432005,0.0002801756],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4702572,0.1781081,0.008448874,0.001488301,0.002067737,0.0006860512,0.000627588,0.005185878,0.1877618,0.0003831759,0.003672245,0.1413129],"study_design_scores_gemma":[0.2852958,0.6899293,0.009379691,0.00004029337,0.0005200561,0.0003501695,0.00006506006,0.001146833,0.01056966,0.0001094086,0.002567594,0.00002607153],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9952103,0.001361093,0.0004323157,0.000177717,0.00007048353,0.001502393,0.0003422766,0.00007117481,0.0008322932],"genre_scores_gemma":[0.9936147,0.001360847,0.001119405,0.0003342545,0.000111153,0.001407569,0.0008227465,0.00002289862,0.001206426],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002252986,"threshold_uncertainty_score":0.006806016,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.160243382824443,"score_gpt":0.5031085037615861,"score_spread":0.3428651209371431,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}